About Index Trending news
Analyze
Top 50 Pricing
Resverlogix Corp.

Resverlogix Corp.

Work at Resverlogix Corp.? Add yourself to this profile

Resverlogix Corp.

RVX-208 is a first-in-class, selective BET bromodomain inhibitor treating patients with cardiovascular disease, diabetes mellitus, and other serious diseases.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO debt
$30,000,000
Post-IPO equity
$2,300,000
Employees

Team size

10+

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Resverlogix Corp. makes some noise.